Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Argent Biopharma ( (AU:RGT) ) has provided an update.
Argent Biopharma Ltd has announced the issuance of convertible notes as part of a new financing agreement with US-based institutional funds managed by C/M Capital Partners, LP. This agreement provides Argent with a substantial funding facility of up to A$11 million, with an initial tranche of A$3 million already secured. The issuance of these convertible notes is expected to increase the company’s cash reserves and potentially double its number of fully paid ordinary shares, enhancing its financial position and operational capabilities.
More about Argent Biopharma
Argent Biopharma Ltd is a company operating in the biopharmaceutical industry, focusing on developing and providing innovative pharmaceutical products. The company is listed on the Australian Securities Exchange under the ticker ASX: RGT and is engaged in securing funding for its operations through financial agreements.
Average Trading Volume: 87,148
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$5.91M
See more data about RGT stock on TipRanks’ Stock Analysis page.